Humacyte, Inc
Hospital
Why pick this one
Humacyte Global, Inc. has FDA-approved Symvess for extremity vascular trauma and manufactures bioengineered vessels at its Durham headquarters.
Best for
- Healthcare organizations seeking a biologic vessel for extremity vascular trauma repair
- Clinical research involving acellular tissue engineered vessels
- Investigational vascular applications including dialysis AV access and peripheral arterial disease
- Regenerative medicine partnerships involving bioengineered human tissues
Look elsewhere if
- Patients seeking general inpatient hospital care
- Routine primary care or emergency department services
- Non-vascular medical treatment unrelated to regenerative tissue products
Specialties
- Acellular tissue engineered vessels
- Extremity vascular trauma repair
- Bioengineered human tissue development
- Investigational dialysis AV access
- Regenerative medicine platform development
Certifications
- U.S. FDA BLA approval for Symvess in extremity vascular trauma
- U.S. FDA Regenerative Medicine Advanced Therapy designation for ATEV
What makes them different
- Symvess is U.S. FDA approved for extremity vascular trauma repair
- The platform is designed to produce universally implantable, off-the-shelf regenerative human tissues
- Manufacturing and processing facilities are located at the Durham, North Carolina headquarters
- The company reports a scalable cell-sourcing and manufacturing platform
- The platform has been used in humanitarian vascular trauma treatment in Ukraine
Distilled from this business's own website.
Contact & Location
- Address
- 2525 N Carolina 54, Durham, NC 27713
- Phone
- 9193139633
- Website
- http://www.humacyte.com/
- customercare@humacyte.com
Services
- Bioengineered tissue research and development
- Bioengineered tissue manufacturing
- Vascular trauma biologic vessel supply
- Clinical research and medical affairs